ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives.
Erratum issuedAbstract readReview
In one paragraph
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- CSF microtubule-associated protein 1 light chain 3A and 3B levels are associated with tau pathology and Alzheimer's disease risk through amyloid deposition and microglial signaling.Journal of neuroinflammation · 2026Article
- Blood tests for Alzheimer's disease could reshape research and care.Nature medicine · 2026Article
- Medical professionals' perspectives and experiences in disclosing a dementia diagnosis: a grounded theory study.BMC geriatrics · 2026Article
- Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- National trends in cerebrospinal fluid biomarker testing for Alzheimer's disease in Japan.Journal of Alzheimer's disease reportsArticle
Corrections and comments
- Erratum issued
Authors and funding
44 authors.
Takeshi IwatsuboDepartment of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Reisa A SperlingCenter for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Alicia Algeciras-SchimnichDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Hidenori AraiNational Center for Geriatrics and Gerontology, Obu, Japan.
Anna M BarronLee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore, Singapore.
Tammie L S BenzingerMallinckrodt Institute of Radiology, Neuroradiology Section, Washington University, St. Louis, Missouri, USA.
Maria C CarrilloMedical & Scientific Relations, Alzheimer's Association, Chicago, Illinois, USA.
Christopher ChenDepartment of Pharmacology, Memory Aging and Cognition Centre, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Seong Hye ChoiDepartment of Neurology, Inha University College of Medicine, Incheon, Republic of Korea.
Igor C FontanaMedical & Scientific Relations, Alzheimer's Association, Chicago, Illinois, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Joshua D GrillDepartments of Psychiatry & Human Behavior and Neurobiology & Behavior, Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, California, USA.
Judith HeidebrinkMichigan Alzheimer's Disease Research Center and Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
Chaur-Jong HuDepartment of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Ryoko IharaDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Takeshi IkeuchiDepartment of Molecular Genetics, Brain Research Institute, Niigata, Japan.
Atsushi IwataDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Fanny C F IpState Key Laboratory of Molecular Neuroscience and Molecular Neuroscience Center, The Hong Kong University of Science and Technology & Hong Kong Center For Neurodegenerative Diseases, Hong Kong SAR, China.
Fasihah Irfani FitriDepartment of Neurology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Jee Hyang JeongDepartment of Neurology, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
Jianping JiaInnovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Nagaendran KandiahDementia Research Centre (Singapore) & Neuroscience and Mental Health Programme, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
SangYun KimDepartment of Neurology, Seoul National University College of Medicine & Clinical Neuroscience Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Hisatomo KowaDepartment of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan.
Renaud La JoieDepartment of Neurology, Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco (UCSF), San Francisco, California, USA.
Yoshiki NiimiUnit for Early and Exploratory Clinical Development, University of Tokyo Hospital, Tokyo, Japan.
Ryoji NoritakeHealth and Global Policy Institute, Otemachi, Tokyo, Japan.
Ozioma C OkonkwoDepartment of Medicine and the Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Sebastian PalmqvistMemory Clinic, Skåne University Hospital, Malmö, Sweden.
Michael S RafiiAlzheimer's Therapeutic Research Institute, Keck School of Medicine of University of Southern California, San Diego, California, USA.
Rema RamanAlzheimer's Therapeutic Research Institute, Keck School of Medicine of University of Southern California, San Diego, California, USA.
Yong ShenNeurodegenerative Disorder Research Center and Brain Bank, University of Science and Technology of China, Hefei, China.
Tanya SimuniDepartment of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Heather M SnyderMedical & Scientific Relations, Alzheimer's Association, Chicago, Illinois, USA.
Orapitchaya SriwannopasDepartment of Internal Medicine, Division of Geriatric Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Nakhon Pathom, Thailand.
Luke E StoeckelDivision of Behavioral and Social Research, National Institute on Aging, Bethesda, Maryland, USA.
Wiesje M van der FlierAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Huali WangDementia Care and Research Center, Peking University Institute of Mental Health (Sixth Hospital), Beijing Municipal Key Lab for Translational Research on Diagnosis and Treatment of Dementia, National Clinical Research Center for Mental Disorders, NHC Key Laboratory for Mental Health, Beijing, China.
Donna M WilcockDepartment of Neurology, Center for Neurodegenerative Disorders, IUSM/IUH Neuroscience Institute and Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Jin ZhouClinical Development Neurology, Eisai Inc., Nutley, New Jersey, USA.
Simin MahinradMedical & Scientific Relations, Alzheimer's Association, Chicago, Illinois, USA.ORCID 0000-0002-5927-7130
Claire E SextonMedical & Scientific Relations, Alzheimer's Association, Chicago, Illinois, USA.
Funding
Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI MICHAEL W WEINER · 2016 to 2026
$226.7MThe Health & Aging Brain Study - Health Disparities (HABS-HD)U19AG078109 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI LEIGH A JOHNSON · 2022 to 2026
$181.1MSmartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS, Suzanne Elizabeth Schindler · 1985 to 2026
$69.5MImaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9MWisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA MethylationR01AG027161 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Nathaniel Ark Chin, Sterling C Johnson · 2007 to 2026
$35.6MResearch Education ComponentP30AG072931 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Henry L Paulson · 2021 to 2026
$26.5MVascular and Behavioral Determinants of Superior Memory Performance from Continuous Monitoring of Everyday ActivitiesU19AG073153 · NIA · UNIVERSITY OF CHICAGO · PI GEULA, CHANGIZ, MESULAM, MAREK-MARSEL M · 2021 to 2025
$19.1MClinical trials to prevent Alzheimer's Disease in Down SyndromeR61AG066543 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RAFII, MICHAEL S · 2019 to 2020
$5.6MLifestyle Risk and Resiliency Factors and Alzheimer’s Disease in Down syndromeR01AG070028 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Sigan L Hartley, Christy Hom · 2020 to 2026
$4.6MLongitudinal Investigation of Cardiorespiratory Fitness and AD Biomarkers in an At-Risk CohortR01AG062167 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI OKONKWO, OZIOMA C · 2019 to 2023
$4.5MRole of estradiol and related hormones on inflammation, sleep, and risks for Alzheimer's diseaseR01AG066203 · NIA · EMORY UNIVERSITY · PI HU, WILLIAM TZU-LUNG, WHARTON, WHITNEY LEE · 2019 to 2023
$3.6MKLOTHO and Resilience to Synaptic Dysfunction in Preclinical ADR01AG077507 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Ira Frahmand, Ozioma C Okonkwo · 2023 to 2026
$3.1MAlexander family professorshipAlzheimer NederlandAlzheimer's Association #ADSF-21-831376-CAlzheimer's Association #ADSF-21-831377-CAlzheimer's Association #ADSF-21-831381-CAlzheimer's Association #ADSF-24-1284328-CAlzheimer's Drug Discovery Foundationanonymous donorAvid RadiopharmaceuticalsBeijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park Z201100005520016Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park Z201100005520017BiogenCombinosticsCure Alzheimer's FundDavis Alzheimer's Prevention ProjectEdwin Bouw fondsEisaiEli Lilly-NLErling-Persson Family FoundationEU Joint Programme - Neurodegenerative Disease Research JPND2021-00694European Partnership on MetrologyEuropean Union's Horizon 2020 research and innovation programmeEuropean Union's Horizon Europe research and innovation programmeFamiljen Rönströms StiftelseFujifilmGates VenturesGHR FoundationGIESKES-STRIJBIS FONDSHealth∼HollandHersenstichtingHjärnfonden FO2022-0270Innovation and Technology Commission - Hong Kong MRP/042/18XInnovation and Technology Commission - Hong Kong MRP/097/20XInnovative Health InitiativeJapan Agency for Medical Research and Development 23re0122003Japan Agency for Medical Research and Development 25dk0207068h0003Japan Agency for Medical Research and Development JP19dk0207048h001Japan Agency for Medical Research and Development JP20dk0207048h002Japan Agency for Medical Research and Development JP21dk0207048h0003Japan Agency for Medical Research and Development JP21dk0207054h0001Japan Agency for Medical Research and Development JP22dk0207048h004Japan Agency for Medical Research and Development JP22dk0207054h0002Japan Agency for Medical Research and Development JP23dk0207048h005Japan Agency for Medical Research and Development JP23dk0207054h0003Japan Agency for Medical Research and Development JP24dk0207054h0004Japan Agency for Medical Research and Development JP24dk0207060Japan Agency for Medical Research and Development JP24dk0207069h0001Japan Society for the Promotion of Science JP24K10653Life-MINational Institute for Health and Care Research University College London Hospitals Biomedical Research CentreNederlandse Organisatie voor Wetenschappelijk OnderzoekNIA NIH HHS P01 AG003991NIA NIH HHS P30 AG072931NIA NIH HHS R01 AG027161NIA NIH HHS R01 AG062167NIA NIH HHS R01 AG066203NIA NIH HHS R01 AG070028NIA NIH HHS R01 AG077507NIA NIH HHS R01 AG085592NIA NIH HHS R61 AG066543NIA NIH HHS RF1 AG052324NIA NIH HHS U19 AG024904NIA NIH HHS U19 AG032438NIA NIH HHS U19 AG073153NIA NIH HHS U19 AG078109NIH HHS P01AG003991NIH HHS P30AG072931NIH HHS R01AG027161NIH HHS R01AG062167NIH HHS R01AG066203NIH HHS R01AG070028NIH HHS R01AG077507NIH HHS R01AG085592NIH HHS R61AG066543NIH HHS RF1AG052324NIH HHS U19AG024904NIH HHS U19AG032438NIH HHS U19AG073153NIH HHS U19AG078109Novarti-NLOlav Thon StiftelsenPasman stichtingPhilipsRoche NederlandStichting DioraphteStichting EquilibrioStiftelsen för Gamla TjänarinnorSwedish State Support for Clinical ResearchThe Science and Technology Innovation 2030-Major Project 2021ZD0201802The Science and Technology Innovation 2030-Major Project 2021ZD0201805Topsector Life Sciences & HealthUK Dementia Research Institute at UCLVetenskapsrådet #2019-02397Vetenskapsrådet #2022-01018Vetenskapsrådet #2023-00356ZonMw
Abstract
The landscape of Alzheimer's disease (AD) and related dementias (ADRD) diagnosis is evolving rapidly, driven by advances in disease understanding, biomarker tools, and disease-modifying therapies. Modern diagnostic approaches emphasize biological precision, early detection, and dynamic frameworks that adapt to treatment-induced changes in disease biology. These frameworks enable opportunities for personalized interventions-encompassing pharmacological and non-pharmacological strategies-and for enhanced clinical trial design. However, implementing these advancements globally is influenced by diverse cultural, infrastructural, and regulatory factors. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis, held in Japan, provided a unique platform to explore these global dynamics, particularly from an Asian perspective. This article highlights key discussions from the conference, exploring the role of biomarker-based diagnostic frameworks in shaping the future of AD/ADRD research, diagnosis, and treatment. We highlight regional challenges and successes and emphasize ethical considerations and practical strategies needed to ensure equitable access to diagnostic and therapeutic innovations. HIGHLIGHTS: Advances in biomarkers are reshaping Alzheimer's disease diagnosis and treatment. Modern diagnostic frameworks highlight biological precision, early detection, and dynamic frameworks. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis explored challenges and opportunities in global biomarker implementation. The conference explored geographic-specific impacts, focusing on Asia.
Indexed as
Alzheimer DiseaseAsiaBiomarkersEarly DiagnosisHumansBiomarkersAlzheimer's diseaseAsiabiomarkerdementiadiagnosis
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.